Handbook of Therapeutic Biomarkers in Cancer
- Available for pre-order. Item will ship after February 1, 2021
This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists and will also be useful for patients and general readers interested in the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.
Sherry X. Yang is a physician and program director of the Cancer Diagnosis Program, National Cancer Institute (NCI), USA. She serves as a member of the Biomarker Review Committee of the NCI-sponsored clinical trials and the NCI ComboMATCH Molecular Biomarker and Specimen Management Committee. Dr. Yang was chief of National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, NCI, from 2006 to 2019. She has implemented the translational oncology research initiative for predictive and prognostic biomarkers in cancer treatment toward precision medicine. Her team recently discovered the performance of prognostic factors, including breast cancer subtypes, that was driven by treatment modality and weighted by the type of clinical endpoints with reference to untreated patients. She is a recipient of several biomarker-related awards and innovations.
Janet E. Dancey is director of the Canadian Cancer Trials Group and professor in the Department of Oncology, Queen's University, Canada. Previously, she was associate chief of the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the NCI, USA. In her current position, Dr. Dancey is responsible for the development and oversight of CCTG clinical trials activities. Her clinical focus is on melanoma and gastrointestinal malignancies.